Early Efficacy of Taxotere and Cisplatin Chemo-Radiotherapy for Advanced Cervical Cancer

  • Ke, Qing-Hua (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou) ;
  • Zhou, Shi-Qiong (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou) ;
  • Du, Wei (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou) ;
  • Lei, Yong (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou) ;
  • Huang, Min (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou) ;
  • Luo, Fei (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou) ;
  • Yang, Ji-Yuan (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
  • Published : 2012.02.29


The aim of this study was to investigate the early outcome of the taxotere and cisplatin chemoradiotherapy for advanced cervical cancer. Fifty-six cases (FIGO II b to IVa) were divided randomly into two groups: radiotherapy alone (28 cases) and radiation plus chemotherapy (TP) group. There was no difference in radiotherapy between the two groups. The RT+C cases who received TP regimen during the radiation, and DDP once weekly injection of vain, according to 20$mg/m^2$ and taxotere once weekly iv according to 35 $mg/m^2$. These regimens were given for 4~5weeks, and some medicines to control vomiting were available for the RT+C cases. The two groups received an oral medicine MA 160mg every day during the treatment. Regarding early outcome, the complete remission rate was 64.3% and partial remission rate was 35.7% in RT+C. The complete remission rate was 32.1% and partial remission rate was 39.3% in RT. The total response rate and complete remission in the RT+C group were higher than that in the RT group. We conclude that taxotere and cisplatin chemoradiotherapy can improve the early outcome of the advanced cervical cancer, the adverse effects being endurable.


Cervical cancer;taxotere and cisplatin;chemoradiotherapy


  1. Bai XK, Zhao Z (2001). The clinic investigation of the effectiveness of medicine MA on the survival condition of cancer patients in chemotherapy period. Shanxi Oncol Med, 9, 161-2.
  2. Dubay RA, Rose PG, O'Malley DM, et al (2004). Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecol Oncol, 94, 121-4.
  3. Duenas-Gonzalez A, Zarba JJ, Patel F, et al (2011). Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol, 29, 1678-85.
  4. Eifel PJ, Winter K, Morris M, et al (2004). Pelvic irradiation with concurrent chemotherapy versus pelvic and paraaortic irradiation for high- risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol, 22, 872-80.
  5. Green JA, Kirwan JM, Tierney JF, et al (2001). Survival and recurrence after concom itant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet, 358, 781-6.
  6. Higgins RV, Naumann WR, Hall JB, et al (2003). Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecol Oncol, 89, 499-503.
  7. Lorvidhaya V, Chitapanarux I, Sangruchi S, et al (2003). Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervical: a randomized trial. Int J Radiat Oncol Biol Phys, 55, 1226-32.
  8. Lu P, Liang QD, Zheng QQ (2003). Influence of clinical and pathologic parameters on prognosis of cervical carcinoma in China. Chinese-German J Clin Oncol, 2, 163-5.
  9. Morris M, Eifel PJ, Lu J, et al (1999). Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high- risk cervical cancer. N Engl J Med, 340, 1137-43.
  10. Peters WA, Liu PY, Barrett RJ, et al (2000). Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervical. J Clin Oncol, 18, 1606-13.
  11. Pignata S, Frezza P, Tramontana S, et al (2000). Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri. Ann Oncol, 11, 455-9.
  12. Rose PG, Ali S, Watkins E, et al (2007). Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol, 25, 2804-10.
  13. Rose PG, Bundy BN, Watkins EB, et al (1999). Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med, 340, 1144-53.
  14. Sun Y, Zhou JC (2002). 4 Edition. Beijing: People's Medical Publishing House. Manual of medical oncology, 106-418.
  15. Thomas GM (1999). Improved treatment for cervical cancerconcurrent chemotherapy and radiotherapy. N Engl J Med, 340, 1198-200.
  16. Wang HQ (2002). Shenyang: Lianing Sience and Tchnology Publishing House. Malignant tumor chemotherapy regimens norms, 16.

Cited by

  1. Synergistic Anticancer Activity of 5-Aminolevulinic Acid Photodynamic Therapy in Combination with Low-dose Cisplatin on Hela Cells vol.14, pp.5, 2013,
  2. Mechanisms of Hela Cell Apoptosis Induced by Abnormal Savda Munziq Total Phenolics Combined with Chemotherapeutic Agents vol.15, pp.2, 2014,
  3. Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer vol.96, pp.2, 2017,
  4. Effects of curcumin on growth of human cervical cancer xenograft in nude mice and underlying mechanism vol.38, pp.1, 2017,